Senti Biosciences Inc
Research Senti Biosciences Inc (SNTI) on Bullrun: market cap USD 9.78M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSNTI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 9.78M
- Financial periodQ2 2026
- RevenueUSD 17.00K
- Net income-USD 12.75M
- Free cash flow-USD 14.25M
Valuation Snapshot
latest market cap is USD 9.78M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 22.00K | -USD 61.44M | -USD 43.64M | n/a | -2.73 | USD 16.42M | USD 28.89M | USD 5.59M |
| FY2024 | USD 0 | -USD 52.79M | -USD 41.42M | n/a | -12.03 | USD 48.28M | USD 33.54M | USD 25.65M |
| FY2023 | USD 1.98M | -USD 71.06M | -USD 64.43M | n/a | -16.01 | USD 35.93M | USD 37.67M | USD 66.91M |
| FY2022 | USD 3.29M | -USD 58.21M | -USD 76.27M | n/a | -2.23 | USD 57.62M | USD 37.09M | USD 127.26M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 9.78M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 32.11M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 16.95M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 29.40M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 61.84M | n/a | n/a | n/a |
About Senti Biosciences Inc
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Senti Biosciences Inc's market cap?
Senti Biosciences Inc's market capitalization is USD 9.78M.
What does Senti Biosciences Inc do?
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.